Modus Therapeutics Holding AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MODTX.ST research report →
Companywww.modustx.com
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. Its lead product is Sevuparin, a polysaccharide to treat patients with sepsis and septic shock, which is under Phase Ib clinical study. The company was founded in 2011 and is headquartered in Stockholm, Sweden.
- CEO
- John Öhd
- IPO
- 2021
- Employees
- 2
- HQ
- Stockholm, SE
Price Chart
Valuation
- Market Cap
- $40.20M
- P/E
- -2.89
- P/S
- 0.00
- P/B
- 5.91
- EV/EBITDA
- -1.59
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -457.91%
- ROIC
- -200.28%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-18,543,000 · -19.29%
- EPS
- $-0.30 · 30.23%
- Op Income
- $-18,166,000
- FCF YoY
- -23.12%
Performance & Tape
- 52W High
- $5.00
- 52W Low
- $0.21
- 50D MA
- $0.38
- 200D MA
- $0.54
- Beta
- 0.36
- Avg Volume
- 875.40K
Get TickerSpark's AI analysis on MODTX.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our MODTX.ST Coverage
We haven't published any research on MODTX.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MODTX.ST Report →